Storage:Keep tightly closed in a cool, dry place
Authors: Karen G Farrar University of Southern California , Los Angeles, CA, Duy Do Truveta, Inc , Bellevue, WA, Nina B Masters Truveta, Inc , Bellevue, WA, Brianna M Cartwright Truveta, Inc , Bellevue, WA After CVS Caremark made anti-obesity semaglutide the preferred formulary option in July 2025, switching from anti-obesity tirzepatide surged from 0.6% to 9.7%, representing more than a 16-fold rise
10.1007/s12072-020-10070-w 13 LiC.ZhouW.LiM.ShuX.ZhangL.JiG
HK: Conceptualization, Funding acquisition, Writing original draft, Writing review and editing
10.1016/0026-0495(67)90172-2 Metabolism 126 RubensteinA
3 Low-Quality Products 3 Low-Quality Products Supplements without FDA registration, GMP certification, or manufacturing standards may contain contaminants